Affibody has announced the appointment of Peter Zerhouni as Chief Business Officer (CBO).
He will join the Affibody management team and will be responsible for business and corporate development. This appointment strengthens the leadership of key corporate functions as the company enters its next stage of development, states the company.
“We are pleased to welcome Peter to Affibody. His substantial experience from business and corporate development will strengthen our organization at a key point in time as our promising portfolio is moving into late-stage development and multiple business and commercial opportunities are emerging,” says David Bejker, CEO, Affibody.
Peter Zerhouni joins Affibody from a role as Senior Advisor Business Development at BioArctic. Prior to that he served as CEO of InDex Pharmaceuticals where he was responsible for taking the company public and raising more than USD 100 million in public financings.
He also led the development of InDex’s lead asset through Phase 2 and into Phase 3, as well as preparing for commercialization and launch. Prior to that he was with Diamyd Medical both as President and CEO and Director of Business Development. During his time at Diamyd he was responsible for leading the business development efforts that eventually led to a USD 625 million partnership with Johnson & Johnson. Earlier in his career he worked at the global financial institution ING Group.
He holds a MSc in Biology and a BSc in Business Administration and Economics from Lund University and he has also studied at University of California at Berkeley.
Photo of Peter Zerhouni: Kristian Pohl